Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced new employee stock option grants. The company granted non-qualified stock options to three new employees to purchase a total of 22,900 shares of common stock, effective April 1, 2025.
The stock options were issued under Xilio's 2022 Inducement Stock Incentive Plan with an exercise price of $0.7244 per share, matching the closing price on March 31, 2025. The options have a ten-year term and follow a vesting schedule of 25% after the first year, with the remaining 75% vesting in 36 monthly installments, contingent on continued employment.
Xilio Therapeutics (Nasdaq: XLO), un'azienda biotecnologica in fase clinica focalizzata su terapie immuno-oncologiche attivate dai tumori, ha annunciato nuove concessioni di opzioni su azioni per i dipendenti. L'azienda ha concesso opzioni su azioni non qualificate a tre nuovi dipendenti per acquistare un totale di 22.900 azioni di azioni ordinarie, a partire dal 1 aprile 2025.
Le opzioni su azioni sono state emesse nell'ambito del Piano di Incentivazione delle Azioni di Induzione 2022 di Xilio, con un prezzo di esercizio di $0,7244 per azione, corrispondente al prezzo di chiusura del 31 marzo 2025. Le opzioni hanno un termine di dieci anni e seguono un piano di maturazione del 25% dopo il primo anno, con il restante 75% che matura in 36 rate mensili, a condizione di un'occupazione continuativa.
Xilio Therapeutics (Nasdaq: XLO), una empresa de biotecnología en etapa clínica centrada en terapias de inmuno-oncología activadas por tumores, ha anunciado nuevas concesiones de opciones sobre acciones para empleados. La empresa otorgó opciones sobre acciones no calificadas a tres nuevos empleados para comprar un total de 22,900 acciones de acciones ordinarias, con efecto a partir del 1 de abril de 2025.
Las opciones sobre acciones se emitieron bajo el Plan de Incentivos de Acciones de Inducción 2022 de Xilio, con un precio de ejercicio de $0.7244 por acción, que coincide con el precio de cierre del 31 de marzo de 2025. Las opciones tienen un plazo de diez años y siguen un calendario de adquisición del 25% después del primer año, con el 75% restante adquiriéndose en 36 cuotas mensuales, sujeto a empleo continuo.
Xilio Therapeutics (Nasdaq: XLO), 종양 활성화 면역종양학 치료에 집중하는 임상 단계 생명공학 회사가 새로운 직원 주식 옵션 부여를 발표했습니다. 이 회사는 세 명의 신입 직원에게 총 22,900주의 보통주를 구매할 수 있는 비자격 주식 옵션을 부여했습니다. 이는 2025년 4월 1일부터 유효합니다.
주식 옵션은 Xilio의 2022 유도 주식 인센티브 계획에 따라 발행되었으며, 행사 가격은 $0.7244 per share로, 2025년 3월 31일의 종가와 일치합니다. 옵션의 유효 기간은 10년이며, 첫 해 이후 25%가 베스팅되고 나머지 75%는 계속 고용되는 조건으로 36개월에 걸쳐 매달 베스팅됩니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise de biotechnologie en phase clinique axée sur les thérapies d'immuno-oncologie activées par les tumeurs, a annoncé de nouvelles attributions d'options d'achat d'actions pour les employés. L'entreprise a accordé des options d'achat d'actions non qualifiées à trois nouveaux employés pour acheter un total de 22 900 actions ordinaires, à compter du 1er avril 2025.
Les options d'achat d'actions ont été émises dans le cadre du Plan d'Incitation aux Actions d'Induction 2022 de Xilio, avec un prix d'exercice de 0,7244 $ par action, correspondant au prix de clôture du 31 mars 2025. Les options ont une durée de dix ans et suivent un calendrier de vesting de 25 % après la première année, le reste de 75 % étant acquis en 36 versements mensuels, sous réserve d'une poursuite de l'emploi.
Xilio Therapeutics (Nasdaq: XLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf tumoraktivierte Immunonkologie-Therapien konzentriert, hat neue Aktienoptionsvergaben für Mitarbeiter angekündigt. Das Unternehmen hat drei neuen Mitarbeitern nicht qualifizierte Aktienoptionen gewährt, um insgesamt 22.900 Aktien des Stammkapitals zu erwerben, wirksam ab dem 1. April 2025.
Die Aktienoptionen wurden im Rahmen des Xilio 2022 Inducement Stock Incentive Plans mit einem Ausübungspreis von $0,7244 pro Aktie ausgegeben, was dem Schlusskurs am 31. März 2025 entspricht. Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem Vesting-Plan von 25 % nach dem ersten Jahr, wobei die verbleibenden 75 % in 36 monatlichen Raten fällig werden, vorausgesetzt, die Anstellung bleibt bestehen.
- None.
- None.
WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grants and were made as an inducement material to each individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
What is the exercise price for XLO's newly granted stock options in April 2025?
How many shares are covered by XLO's April 2025 inducement stock option grants?
What is the vesting schedule for XLO's April 2025 inducement stock options?
How long is the term of XLO's April 2025 inducement stock options?
